Skip to main content

The Adenosinergic System

A Non-Dopaminergic Target in Parkinson’s Disease

  • Book
  • © 2015

Overview

  • Comprehensive book that discusses all the aspects of this class of drugs in relation to Parkinson's Disease
  • Includes a review on the history of istradefylline
  • Includes a review on urate as a biomarker and neuroprotectant
  • Includes supplementary material: sn.pub/extras

Part of the book series: Current Topics in Neurotoxicity (Current Topics Neurotoxicity, volume 10)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (15 chapters)

Keywords

About this book

Adenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson's Disease and alleviation of symptoms. This book addresses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson's Disease, (2) an overview of neuroimaging studies in human death and disease and (3) a study of urate as a possible biomarker and neuroprotectant.

Reviews

“This is an excellent text on the role of adenosine & its metabolites in parkinson’s disease, cerebral ischemia. … The book will benefit neurologists, pharmacologists, researchers, and biochemists with inical interests.” (Joseph J. Grenier, Amazon.com, January, 2017)

“The authors have gathered updated and high-quality chapters from world-leading experts in the field to provide essential information on the development of novel therapies for the treatment of Parkinson’s disease and related neurodegenerative disorders. … The audience is neuroscientists who work at either the preclinical and/or clinical phases of understanding the underlying mechanisms and novel molecular targets related to the cause and treatment of Parkinson’s disease and related neurodegenerative disorders.” (Thomas L. Pazdernik, Doody’s Book Reviews, December, 2015)

Editors and Affiliations

  • Dept. of Biomedical Sciences Section of Neuropsychopharmacology, University of Cagliari, Cagliari, Italy

    Micaela Morelli, Nicola Simola

  • Dept. of Neuropsychopharmacology Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

    Jadwiga Wardas

About the editors

Micaela Morelli is a Professor of Pharmacology in the Department of Biomedical Sciences at the University of Cagliari. She also belongs to the Institute of Neuroscience at the National Research Council of Italy (CNR), the Center of Excellence for Neurobiology of Dependence at the University of Cagliari and is a member of the PhD school in Neuroscience at the University of Cagliari. Professor Morelli served in the Governing Councils of the Italian Neuroscience Society (SINS) and the International Basal Ganglia Society (IBAGS). Since 2005, she has been the Italian representative in the International Brain Research Organization (IBRO), and since 2010 she has been a member of the IBRO WERC/PERC Governing Council. Her main subjects of investigation focus on the mechanism of action of drugs affecting dopaminergic and adenosinergic transmission and their interaction in rodent models of Parkinson's disease.

Dr. Nicola Simola holds a M.S. in Pharmaceutical Chemistry and a Ph. D in Pharmacology of Drug Dependence and he is currently Assistant Professor of Pharmacology at the Department of Biomedical Sciences at the University of Cagliari. Dr. Simola’s research involves the study and development of new therapeutic agents for the treatment of Parkinson’s disease, focusing on adenosine receptor antagonists, the development of new preclinical models of early-stage Parkinson’s disease and the study of the interactions between caffeine and other recreational psychostimulants. Moreover, a recent field of Dr Simola’s research focuses on the study of ultrasonic vocalizations in rats as a tool for the study of the addictive properties of drugs.

Jadwiga Wardas Ph.D., graduated from the Jagiellonian University in Krakow, Poland with an MSc in biology. In 1988 she was granted a fellowship from the National Academy of Sciences, USA. She holds a Ph.D. in Life Sciences from the Institute of Pharmacology, Polish Academy of Sciences (IPh PAN). She served as

Associate Professor at the Department of Neuropsychopharmacology, IPh PAN in 2004. She has been awarded numerous competitive research grants by the State Committee for Scientific Research and National Science Centre. Her scientific interests focus on the pathophysiology and therapy of Parkinson’s disease and development of animal models of both presymptomatic and symptomatic phase of this disease. For many years she has studied the involvement of adenosine and dopamine receptors in anti parkinsonian and neuroprotective effects. Her work was awarded twice by the Polish Academy of Sciences and she received the Silver Cross of Merit (2004). She is a member of Polish Neuroscience Society and European College of Neuropsychopharmacology.

Bibliographic Information

  • Book Title: The Adenosinergic System

  • Book Subtitle: A Non-Dopaminergic Target in Parkinson’s Disease

  • Editors: Micaela Morelli, Nicola Simola, Jadwiga Wardas

  • Series Title: Current Topics in Neurotoxicity

  • DOI: https://doi.org/10.1007/978-3-319-20273-0

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer International Publishing Switzerland 2015

  • Hardcover ISBN: 978-3-319-20272-3Published: 15 September 2015

  • Softcover ISBN: 978-3-319-37186-3Published: 22 October 2016

  • eBook ISBN: 978-3-319-20273-0Published: 01 October 2015

  • Series ISSN: 2363-9563

  • Series E-ISSN: 2363-9571

  • Edition Number: 1

  • Number of Pages: XII, 337

  • Number of Illustrations: 10 b/w illustrations, 31 illustrations in colour

  • Topics: Neurosciences, Neurology

Publish with us